Founders Capital Management (Texas)’s Lisata Therapeutics LSTA Stock Holding History

Founders Capital Management (Texas)’s Portfolio LSTA Stock Details LSTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.67K	Hold	1,667	–	–	﹤0.01%	363
2026 Q1	$8.35K	Hold	1,667	–	–	﹤0.01%	325
2025 Q4	$3.1K	Sell	1,667 -333	-17%	-$740	﹤0.01%	355
2025 Q3	$5.24K	Hold	2,000	–	–	﹤0.01%	327
2025 Q2	$5.8K	Hold	2,000	–	–	﹤0.01%	309
2025 Q1	$4.7K	Hold	2,000	–	–	﹤0.01%	310
2024 Q4	$5.96K	Hold	2,000	–	–	﹤0.01%	300
2024 Q3	$6K	Hold	2,000	–	–	﹤0.01%	309
2024 Q2	$6.94K	Buy	2,000 +1,667	+501%	+$5.08K	﹤0.01%	302
2024 Q1	$1.04K	Hold	333	–	–	﹤0.01%	336
2023 Q4	$909	Sell	333 -333	-50%	-$782	﹤0.01%	363
2023 Q3	$1.43K	Hold	666	–	–	﹤0.01%	376
2023 Q2	$2.46K	Hold	666	–	–	﹤0.01%	356
2023 Q1	$2K	Hold	666	–	–	﹤0.01%	364
2022 Q4	$2K	Hold	666	–	–	﹤0.01%	358
2022 Q3	$3K	Sell	666 -1	-0.1%	-$7	﹤0.01%	357
2022 Q2	$5K	Buy	667 +334	+100%	+$2.75K	﹤0.01%	367
2022 Q1	$4K	Hold	333	–	–	﹤0.01%	292
2021 Q4	$4K	Sell	333 -667	-67%	-$10.3K	﹤0.01%	292
2021 Q3	$18K	Hold	1,000	–	–	0.01%	225
2021 Q2	$24K	Buy	+1,000	New	+$23.7K	0.02%	186

Other funds holding LSTA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

Founders Capital Management (Texas)'s LSTA Position: Q2 2026 in Review

Founders Capital Management (Texas) held its Lisata Therapeutics (LSTA) position steady in Q2 2026 at 1,667 shares worth $5.67K. The position accounts for ﹤0.01% of the portfolio, ranked #363.

Founders Capital Management (Texas) first reported a position in LSTA in Q2 2021 and has held it in 21 quarters since. The position peaked at $24K in Q2 2021. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

Founders Capital Management (Texas) held 1,667 shares of Lisata Therapeutics worth $5.67K as of Q2 2026.
Founders Capital Management (Texas) left its Lisata Therapeutics share count unchanged in Q2 2026.
Lisata Therapeutics made up ﹤0.01% of Founders Capital Management (Texas)'s portfolio in Q2 2026, its #363 holding.
Founders Capital Management (Texas) first reported a position in Lisata Therapeutics in Q2 2021 and has held it in 21 quarters since.
Founders Capital Management (Texas)'s Lisata Therapeutics position peaked at $24K in Q2 2021.
31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q2 2026, filed 21 Jul 2026.